ALEVA NEUROTHERAPEUTICS SA  |  EPFL INNOVATION PARK - BUILDING D  |  1015 LAUSANNE  |  SWITZERLAND  |  INFO@ALEVA-NEURO.COM

Aleva Neurotherapeutics 

has developed a proprietary neurostimulation platform based on MEMS Technology that enables significantly better therapies for neurological diseases.

Deep Brain Stimulation (DBS) therapy, used in indications including Parkinsonʼs Disease, is an existing market growing at over 10% annually and is Alevaʼs first target market.

 

With Alevaʼs products, neurosurgeons and neurologists will see reduced surgical and follow-up times, patients will benefit from a decrease in debilitating side effects, and payers will see a reduction in cost-of-care.

Alevaʼs technology can decrease the complications and side effects associated with DBS therapy.